Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00745550 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
A Phase 1 study, sponsored by S*BIO.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00745550 is a Phase 1 study that has completed, run by S*BIO. The registered enrollment target is 55 participants.
The verdict
NCT00745550, a Phase 1 study, has completed, sponsored by S*BIO.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with Chronic Idiopathic Myelofibrosis (CIMF) regardless of their JAK2 mutational status. The second portion of the study is a Phase 2 study to define the efficacy and safety profile of single agent SB1518 at the recommended dose in subjects with CIMF.
Interventions
- DRUG SB1518
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00745550
The ClinicalTrials.gov registry entry for NCT00745550 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is S*BIO, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB1518 is the first listed.
NCT00745550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00745550 about?
NCT00745550 is a clinical study titled "A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis". The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with Chronic Idiopathic Myelofibrosis (CIMF) regardless of...
What is the current status of trial NCT00745550?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2008-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00745550?
The interventions under investigation include: SB1518 (DRUG).
Who is sponsoring clinical trial NCT00745550?
This trial is sponsored by S*BIO, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.